MARKET NEWS

Moderna Announces First Participant Dosed in Phase 3 Pivotal Registration Study of its mRNA Cytomegalovirus (CMV) Vaccine
Halberd Files Provisional Patent on Breakthrough Obesity Treatment
Evaxion Biotech Announces Clinical Collaboration to Evaluate Lead Product Candidate with KEYTRUDA (pembrolizumab) in Patients With Melanoma
TCR² Therapeutics Announces Clinical Trial Collaboration Agreement With Bristol Myers Squibb
Krystal Biotech Announces Completion of the GEM-3 Pivotal Phase 3 Study Evaluating B-VEC for the Treatment of Dystrophic Epidermolysis Bullosa
Catalent's Investment in Expanding its State-of-the-Art Gene Therapy Commercial Manufacturing Campus Increases to $360 Million

  FEATURED EDITORIAL


  COMPANY PROFILE

Medical Engineering Technologies delivers excellence in combination device testing, globally. Services include: biocompatibility and chemical characterization, dose delivery accuracy, extractable and leachable studies, formulation stability, mechanical performance, RLD comparisons, sterile barrier verification, human factors studies, and lots of good advice. Medical Engineering Technologies is the destination for combination device batch release and design validation testing. Clients from across the globe have found our laboratory services to be rapid, precise, and very effective. MET has successfully delivered testing to medical device and pharmaceutical companies in over 20 countries across: Africa, Asia, Australasia, Europe, and the USA. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Nemera Launches UniSpray, its Unidose System Primarily for Systemic-Acting Drug Administration

Nemera Launches UniSpray, its Unidose System Primarily for Systemic-Acting Drug Administration

Nemera has a proven track record in developing and manufacturing complex Ear Nose and Throat solutions. In line with clear growing market interest in unidose system coupled with promising advantages that nasal route could….

Ocugen, Inc. Announces Submission of IND to Initiate a Phase 3 Clinical Trial Evaluating COVID-19 Vaccine Candidate

Ocugen, Inc. Announces Submission of IND to Initiate a Phase 3 Clinical Trial Evaluating COVID-19 Vaccine Candidate

Ocugen, Inc. recently announced that it has submitted an Investigational New Drug application (IND) with the US FDA to evaluate the COVID-19 vaccine….

Aptinyx Completes Enrollment in Phase 2b Study of NYX-2925 in Painful Diabetic Peripheral Neuropathy

Aptinyx Completes Enrollment in Phase 2b Study of NYX-2925 in Painful Diabetic Peripheral Neuropathy

Aptinyx Inc. recently announced the completion of enrollment in the company’s ongoing Phase 2b study of NYX-2925 for the treatment of painful diabetic peripheral neuropathy….

Cybrexa Therapeutics Announces Data Demonstrating Early Signals of Efficacy & Powerful Potential of Antigen-Independent Tumor Targeting

Cybrexa Therapeutics Announces Data Demonstrating Early Signals of Efficacy & Powerful Potential of Antigen-Independent Tumor Targeting

Cybrexa Therapeutics recently announced favorable early Phase 1 data for its lead therapeutic candidate, CBX-12 (alphalex-exatecan). The initial data show robust….

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

November 10 – Prefilled Syringes
November 17 – Injection Devices